Clene Inc. CEO to Present at Investor Summit Virtual, Highlighting Progress in Neurodegenerative Disease Treatment

Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, has announced that its CEO and President, Rob Etherington, is set to present at the Investor Summit Virtual on June 10. This presentation will provide investors with an update on Clene's progress and strategic outlook, particularly focusing on its innovative approach to treating neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.

The company's flagship investigational therapy, CNM-Au8®, represents a first-in-class treatment aimed at enhancing mitochondrial health and protecting neuronal function. By targeting mitochondrial function and the NAD pathway while reducing oxidative stress, CNM-Au8® offers a novel mechanism of action that could significantly impact the treatment landscape for neurodegenerative diseases. Clene's commitment to advancing this therapy underscores the potential for meaningful advancements in patient care and outcomes.

This update is crucial for investors and the broader medical community as it highlights the ongoing efforts to address some of the most challenging neurodegenerative conditions. The presentation at the Investor Summit Virtual will shed light on Clene's strategic direction and the progress of CNM-Au8®, offering insights into the future of neurodegenerative disease treatment. The implications of Clene's work extend beyond the biopharmaceutical industry, promising hope for patients and families affected by these debilitating diseases.